Harte Group Expands Global Network to Support Pharmaceutical Companies
Doylestown, Pa.
Harte Group, a global company who manages and represents Functional Service Providers for support of clinical development needs, announced that its growing network of partners has reached 44 companies, employing over 7,900 experienced staff with an average company life of 13 years in business.
Due to a changing landscape within clinical development operations and the market being underserved by the existing full-service CRO model, the Harte Group created a full-service CRO offering - one built by leveraging smaller companies. Many sponsors have been looking for alternatives to support smaller programs in their portfolio, as well as looking for more ways to execute their clinical programs and projects.
"I am excited by the high level of interest in this Functional Services Provider model," said Michael Harte, Founder & President of the Harte Group. Harte mentioned that their team is in active discussions with both large pharma and smaller biotechnology firms.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
